EHJ - Cardiovascular Pharmacotherapy

Focusing on clinical cardiovascular pharmacology

  • Years
  • Topics
  • Special Options

Showing 24 of 902 results

Advancing and implementing cardiovascular drug therapy
ESC Journals
Advancing and implementing cardiovascular drug therapy
4 November 2026
See more
Rewriting heart health: epigenetic drugs in cardiovascular medicine
ESC Journals
Rewriting heart health: epigenetic drugs in cardiovascular medicine
24 September 2026
See more
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
ESC Journals
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
23 September 2026
See more
Universal evidence and contextual pharmacotherapy
ESC Journals
Universal evidence and contextual pharmacotherapy
22 September 2026
See more
From digital reminders to artificial intelligence–enabled understanding: can personalized treatment predictions improve therapeutic adherence?
ESC Journals
From digital reminders to artificial intelligence–enabled understanding: can personalized treatment predictions improve therapeutic adherence?
22 September 2026
See more
Can ARNI prevent atrial fibrillation in heart failure with reduced ejection fraction? Real-world evidence meets the randomized benchmark
ESC Journals
Can ARNI prevent atrial fibrillation in heart failure with reduced ejection fraction? Real-world evidence meets the randomized benchmark
22 September 2026
See more
Reply to Erre et al: translating cardio-rheumatology into practice: a multi-level pilot network
ESC Journals
Reply to Erre et al: translating cardio-rheumatology into practice: a multi-level pilot network
16 September 2026
See more
Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome
ESC Journals
Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome
16 September 2026
See more
Switching to angiotensin receptor–neprilysin inhibitor and reduced risk of new-onset atrial fibrillation in heart failure with reduced ejection fraction: a nationwide propensity score–matched study
ESC Journals
Switching to angiotensin receptor–neprilysin inhibitor and reduced risk of new-onset atrial fibrillation in heart failure with reduced ejection fraction: a nationwide propensity score–matched study
15 September 2026
See more
Translating cardiorheumatology into practice: a multilevel pilot network
ESC Journals
Translating cardiorheumatology into practice: a multilevel pilot network
11 September 2026
See more
Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort
ESC Journals
Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort
10 September 2026
See more
Vagal activity-related events and glucagon-like peptide-1 receptor agonists
ESC Journals
Vagal activity-related events and glucagon-like peptide-1 receptor agonists
8 September 2026
See more
Response to Lu Li and colleagues
ESC Journals
Response to Lu Li and colleagues
1 September 2026
See more
Comparative biomarker efficacy of cholesteryl ester transfer protein inhibitors: a network meta-analysis
ESC Journals
Comparative biomarker efficacy of cholesteryl ester transfer protein inhibitors: a network meta-analysis
28 August 2026
See more
PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
ESC Journals
PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
26 August 2026
See more
Clinical and experimental insights into hydroxychloroquine-associated electrical abnormalities and cardiomyopathy
ESC Journals
Clinical and experimental insights into hydroxychloroquine-associated electrical abnormalities and cardiomyopathy
25 August 2026
See more
Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy
ESC Journals
Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy
17 August 2026
See more
Pharmacokinetics in the Fontan circulation: a multi-organ puzzle
ESC Journals
Pharmacokinetics in the Fontan circulation: a multi-organ puzzle
10 August 2026
See more
May the universal truth rest in peace and us with her? On how to understand inconsistency in and among pharmacological trials
ESC Journals
May the universal truth rest in peace and us with her? On how to understand inconsistency in and among pharmacological trials
5 August 2026
See more
Authors’ reply to: ‘Stent-free is not risk-free: risk-defined DAPT after DCB-only PCI in ACS’
ESC Journals
Authors’ reply to: ‘Stent-free is not risk-free: risk-defined DAPT after DCB-only PCI in ACS’
4 August 2026
See more
Correction to: Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation
ESC Journals
Correction to: Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation
28 July 2026
See more
From ‘bridging specialties’ to ‘owning the patient’: rethinking accountability in Cardiovascular-Kidney-Metabolic syndrome care
ESC Journals
From ‘bridging specialties’ to ‘owning the patient’: rethinking accountability in Cardiovascular-Kidney-Metabolic syndrome care
27 July 2026
See more
Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis
ESC Journals
Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis
22 July 2026
See more
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence
ESC Journals
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence
17 July 2026
See more

ESC 365 is supported by

Lilly Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources